---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-150395"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:24:28.241684+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Spyre Therapeutics updates share count: 50.8M actual, 65.3M pro forma

## Summary
- As of May 29, 2024, common shares outstanding: 50,782,384.
- Pro forma shares (incl. Series A & B preferred conversion): ~65.3 million.
- Conversion of Series B Preferred was effective per prior 8-K filed May 15, 2024.

## SEC filing metadata
- accession: 0001193125-24-150395
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312524150395/0001193125-24-150395-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312524150395/d806070d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-150395
- JSON: https://secwatch.observer/filing/0001193125-24-150395.json
- Plain text: https://secwatch.observer/filing/0001193125-24-150395.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.